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Objective
AIDS-associated Kaposi's Sarcoma (KS) is an increasing
public health problem in KwaZulu-Natal, South Africa.
The optimal management of AIDS-associated KS in sub-
Saharan Africa is unknown. NCT00380770 is a single
center randomized clinical trial of 112 patients with
AIDS-associated KS who received a nivirapine based anti-
viral regimen (ARV) alone, or with chemotherapy (doxo-
rubicin, bleomycin and vincristine) between 2003 and
2007. We evaluated 1-year overall survival (OS) and the
ACTG staging system in our study population.
Design
Cohort study.
Methods
Baseline TIS staging information is available for all
patients. One-year survival data is available for 105 study
subjects, with only seven subjects lost to follow-up. OS
was evaluated using Kaplan-Meier hazard function meth-
odology. Survival functions were generated for subjects
with 0, 1, 2 and 3 adverse prognostic variables using the
modified ACTG TIS staging system (CD4 cut-off = 150).
Univariate and multivariate Cox proportional hazard
regression was performed to evaluate the prognostic value
of individual and combined variables on OS in the study
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Table 1: Baseline demographics
Randomization ARV 53%
Combination 47%
Sex F 55% M = 45%
Age Range 18–62
Region Urban 70% Rural 30%
T 0 = 14% 1 = 86%
I 0 = 45% 1 = 55%
S 0 = 56% 1 = 44%Publish with BioMed Central    and   every 
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cohort. Survival analysis was performed with Stata 10 for
Macintosh.
Results
Baseline characteristics are listed in Table 1. One-year OS
in the overall cohort was 76.6 percent. For subjects with 0,
1, 2 and 3 adverse prognostic risk factors, the one-year OS
was 100 percent, 89 percent, 73 percent and 61 percent
(Figure 1). Results from univariate and multivariate Cox
proportional hazard regression analyses are listed in Table
2. For the Cox proportional hazards regression model
including T, I, and S, the LR χ2 (3) = 8.45, with p = 0.0375.
Conclusion
In NCT00380770, 1-year OS in a cohort of AIDS-associ-
ated KS subjects in a resource limited setting is dramati-
cally improved compared to historical sub-Saharan
cohorts prior to the availability of ARVs. The ACTG Stag-
ing system is clinically useful in resource-limited settings.
It is notable that for 86 percent T = 1 disease and universal
ARV use HIV-associated systemic illnesses, which
included 15 subjects with tuberculosis, is the most signif-
icant prognostic factor. Analysis of response rates, overall
survival, adverse events, and quality-of-life between the
two arms in NCT00380770 is ongoing.
Table 2: Cox Proportional Hazard Regression
Prognostic variable Univariate Multivariate
T HR = 2 p = 0.34 HR = 1.8 p = 0.44
I HR = 2 p = 0.11 HR = 1.8 p = 0.16
S HR = 2.7 p = 0.02 HR = 2.4 p = 0.04
HR = Hazard ratio of death for score of 1 compared to score of 0
Overall survival Figure 1
Overall survival.